Movement Alert｜BeiGene Rises 3.05% in Regular Trading, Tevimbra Esophageal Cancer Indication FDA Filing Acceptance Continues to Catalyze

Market Focus06-24

On June 24, BeiGene (06160.HK) rose 3.05% in regular trading, trading at 165.8 HKD/share, with turnover of 53.15 million HKD.

On the news front, BeiGene recently announced that its supplemental Biologics License Application for Tevimbra targeting esophageal squamous cell carcinoma has been accepted by the U.S. FDA, marking a key milestone in the overseas indication expansion of its core PD-1 antibody product. Additionally, the company reported Q1 net profit attributable to shareholders surging 1,801.3% year-over-year, with gross margin approaching 90%, reflecting sustained fundamental improvement.

Within the Biotechnology sector, the overall tone was positive. Among individual stocks, Innovent Biologics rose 2.55%, Akeso rose 1.64%, 3SBio rose 0.18%, and Ascletis gained 0.10%, with sector linkage providing additional support for BeiGene's continued upward momentum following a technical rebound from the prior session's pullback.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154653019?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154653019","market":"hk","top_or_hot":-1,"title":"Movement Alert｜BeiGene Rises 3.05% in Regular Trading, Tevimbra Esophageal Cancer Indication FDA Filing Acceptance Continues to Catalyze","media":"Market Focus","content":"<p><p>On June 24, BeiGene (06160.HK) rose 3.05% in regular trading, trading at 165.8 HKD/share, with turnover of 53.15 million HKD.</p><p>On the news front, BeiGene recently announced that its supplemental Biologics License Application for Tevimbra targeting esophageal squamous cell carcinoma has been accepted by the U.S. FDA, marking a key milestone in the overseas indication expansion of its core PD-1 antibody product. Additionally, the company reported Q1 net profit attributable to shareholders surging 1,801.3% year-over-year, with gross margin approaching 90%, reflecting sustained fundamental improvement.</p><p>Within the Biotechnology sector, the overall tone was positive. Among individual stocks, Innovent Biologics rose 2.55%, Akeso rose 1.64%, 3SBio rose 0.18%, and Ascletis gained 0.10%, with sector linkage providing additional support for BeiGene's continued upward momentum following a technical rebound from the prior session's pullback.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BeiGene Rises 3.05% in Regular Trading, Tevimbra Esophageal Cancer Indication FDA Filing Acceptance Continues to Catalyze</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BeiGene Rises 3.05% in Regular Trading, Tevimbra Esophageal Cancer Indication FDA Filing Acceptance Continues to Catalyze\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-24 09:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 24, BeiGene (06160.HK) rose 3.05% in regular trading, trading at 165.8 HKD/share, with turnover of 53.15 million HKD.</p><p>On the news front, BeiGene recently announced that its supplemental Biologics License Application for Tevimbra targeting esophageal squamous cell carcinoma has been accepted by the U.S. FDA, marking a key milestone in the overseas indication expansion of its core PD-1 antibody product. Additionally, the company reported Q1 net profit attributable to shareholders surging 1,801.3% year-over-year, with gross margin approaching 90%, reflecting sustained fundamental improvement.</p><p>Within the Biotechnology sector, the overall tone was positive. Among individual stocks, Innovent Biologics rose 2.55%, Akeso rose 1.64%, 3SBio rose 0.18%, and Ascletis gained 0.10%, with sector linkage providing additional support for BeiGene's continued upward momentum following a technical rebound from the prior session's pullback.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1154653019","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154653019","pubTimestamp":1782265009,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 24, BeiGene (06160.HK) rose 3.05% in regular trading, trading at 165.8 HKD/share, with turnover of 53.15 million HKD.On the news front, BeiGene recently announced that its supplemental...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"运动快讯|百济神州常规交易涨3.05%Tevimbra食管癌适应症FDA备案受理持续催化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"On June 24, BeiGene (06160.HK) rose 3.05% in regular trading, trading at 165.8 HKD/share, with turnover of 53.15 million HKD.On the news front, BeiGene recently announced that its supplemental Biologics License Application for Tevimbra targeting esophageal squamous cell carcinoma has been accepted by the U.S. FDA, marking a key milestone in the overseas indication expansion of its core PD-1 antibody product. Additionally, the company reported Q1 net profit attributable to shareholders surging 1,801.3% year-over-year, with gross margin approaching 90%, reflecting sustained fundamental improvement.Within the Biotechnology sector, the overall tone was positive. Among individual stocks, Innovent Biologics rose 2.55%, Akeso rose 1.64%, 3SBio rose 0.18%, and Ascletis gained 0.10%, with sector linkage providing additional support for BeiGene's continued upward momentum following a technical rebound from the prior session's pullback.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154653019","isCrawlerRequest":true}